http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 NEWTON, Mass., November 12, 2009 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that... http://pharmalicensing.com/redirs/news_rss//public/news/view/499902/1/0/novelos-therapeutics-closes-last-tranche-in-9-million-private-placement http://pharmalicensing.com/redirs/news_rss//public/news/view/499902/1/0/novelos-therapeutics-closes-last-tranche-in-9-million-private-placement FARMINGDALE, N.Y., November 12, 2009 -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and... http://pharmalicensing.com/redirs/news_rss//public/news/view/499911/1/0/misonix-announces-new-distribution-agreement-for-saudi-arabia-and-other-middle-eastern-countries http://pharmalicensing.com/redirs/news_rss//public/news/view/499911/1/0/misonix-announces-new-distribution-agreement-for-saudi-arabia-and-other-middle-eastern-countries INDIANAPOLIS and CHICAGO - (Nov. 11, 2009) - Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, and Chromatin Inc. announced today that the companies have entered into two... http://pharmalicensing.com/redirs/news_rss//public/news/view/499753/1/0/dow-agrosciences-chromatin-announce-research-license-agreements http://pharmalicensing.com/redirs/news_rss//public/news/view/499753/1/0/dow-agrosciences-chromatin-announce-research-license-agreements Hull, UK -11 November 2009 The Advanced Wound Management division of Smith & Nephew plc (LSE: SN; NYSE: SNN), announces the signing of a definitive agreement to acquire substantially all of the... http://pharmalicensing.com/redirs/news_rss//public/news/view/499773/1/0/smith-nephew-announces-plan-to-acquire-the-assets-of-nucryst-pharmaceuticals-corp http://pharmalicensing.com/redirs/news_rss//public/news/view/499773/1/0/smith-nephew-announces-plan-to-acquire-the-assets-of-nucryst-pharmaceuticals-corp EWING, N.J.--November 11, 2009--Antares Pharma, Inc. (NYSE Amex: AIS) today announced the simultaneous signing of a license and an asset purchase agreement with Ferring International Center S.A.... http://pharmalicensing.com/redirs/news_rss//public/news/view/499800/1/0/antares-pharma-inc-antr-enters-into-license-and-asset-purchase-agreements-with-ferring-majority-of-antares-employees-will-become-employees-of-ferring http://pharmalicensing.com/redirs/news_rss//public/news/view/499800/1/0/antares-pharma-inc-antr-enters-into-license-and-asset-purchase-agreements-with-ferring-majority-of-antares-employees-will-become-employees-of-ferring Mississauga, Ontario, Canada - November 11, 2009 - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to... http://pharmalicensing.com/redirs/news_rss//public/news/view/499711/1/0/nuvo-research-provides-wf10-licensing-and-development-update http://pharmalicensing.com/redirs/news_rss//public/news/view/499711/1/0/nuvo-research-provides-wf10-licensing-and-development-update ROCKVILLE, MD (November 11, 2009) - Novavax, Inc. (NASDAQ: NVAX) a clinical-stage vaccine company, announced today that John Trizzino, Senior Vice President, International and Government Alliances,... http://pharmalicensing.com/redirs/news_rss//public/news/view/499714/1/0/novavax-to-present-at-the-influenza-congress-usa-2009 http://pharmalicensing.com/redirs/news_rss//public/news/view/499714/1/0/novavax-to-present-at-the-influenza-congress-usa-2009 November 11, 2009 -- Nippon Kayaku Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Koichiro Shimada) concluded the agreement on apaziquone (generic name) for non-muscle invasive bladder... http://pharmalicensing.com/redirs/news_rss//public/news/view/499715/1/0/conclusion-of-the-agreement-on-apaziquone-for-non-muscle-invasive-bladder-cancer http://pharmalicensing.com/redirs/news_rss//public/news/view/499715/1/0/conclusion-of-the-agreement-on-apaziquone-for-non-muscle-invasive-bladder-cancer Milan (Italy), 11 November 2009 - MolMed S.p.A. (Milan:MLM) announces that the European Commission has granted Orphan Drug designation for MolMed's investigational new antitumour therapeutic drug... http://pharmalicensing.com/redirs/news_rss//public/news/view/499722/1/0/the-european-commission-grants-orphan-drug-designation-for-ngr-htnf-in-the-treatment-of-hepatocellular-carcinoma http://pharmalicensing.com/redirs/news_rss//public/news/view/499722/1/0/the-european-commission-grants-orphan-drug-designation-for-ngr-htnf-in-the-treatment-of-hepatocellular-carcinoma Indianapolis and Chicago - November 11, 2009--Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, and Chromatin Inc. announced today that the companies have entered into two... http://pharmalicensing.com/redirs/news_rss//public/news/view/499725/1/0/dow-agrosciences-chromatin-announce-research-license-agreements http://pharmalicensing.com/redirs/news_rss//public/news/view/499725/1/0/dow-agrosciences-chromatin-announce-research-license-agreements